Listen to the latest episode of the ASBMB's science policy podcast with Public Affairs Director Benjamin Corb.

Find all of the Pipettes & Politics episodes on Soundcloud, or subscribe wherever you get your podcasts.


Remote study sections

The coronavirus pandemic has forced federal agencies to move study sections to virtual settings, allowing reviews to continue while also allowing reviewers to follow federal guidance restricting travel and personal interactions.

In an effort to measure and understand the impact that remote peer review might have on science (positive or negative) the ASBMB encourages you to take a moment and share your thoughts and experiences regarding online study sections.

The color of COVID

In a summer dominated by COVID-19 and protests against racial injustice, there are growing demands that drugmakers and investigators ensure that vaccine trials reflect the entire community.

Developing an effective COVID-19 vaccine

Our bodies have two main types of T cells. Together they can help us fend off this virus

What are the advantages of an mRNA vaccine for COVID-19?

They’re easier to manufacture than traditional vaccines, but scientifically their history is checkered

NIH project homes in on COVID racial disparities

Amid a wavering federal response that has allowed staggering levels of disease to sweep the country, the All of Us program is a potential bright spot.

The time of trials: Waiting for a coronavirus vaccine

An infected and impatient world needs protection from Covid-19, but rushing it won't be easy. How can we speed up a complicated process?

We are here because we choose to be

Five months into a pandemic with arguably the world’s worst response, the United States can no longer take the easy way out and blame only politics for our downfall. We’re to blame, too.

How 'good' does a COVID-19 vaccine need to be?

New study finds that a coronavirus vaccine’s effectiveness may have to be higher than 70% or even 80% before Americans can safely stop relying on social distancing.

COVID-19 retractions show that the science is working as it should

Severe scrutiny of two major papers, including one about the effectiveness of hydroxychloroquine, is part of science's normal process of self-correction, explains Mark R. O’Brian.

How can labs reopen safely?

Labs are trying to reopen and get back to research while not spreading COVID-19. Great goal, but how do we do that?

The bat-virus détente

Bats cope with myriad viruses, including the one causing Covid-19, with few ill effects. Scientists are probing their immune systems to fathom how they do it. The answers might help infected people, too.

Resources from the ASBMB


COVID-19 resources and guidance from funding agencies

See our list of guidance and resources from the NSF, NIH, DOE and others.


Online teaching: Practices and resources

A collection of resources for instructors in biochemistry, molecular biology and related fields as they make a transition to remote learning.


Slipping past the proofreader

The virus that causes COVID-19 has its own superpower. Can new drug candidates overcome it?

Other resources

COVID-19 resources for librarians, campuses and health professionals
Access to coronavirus research, textbooks, text and data mining, and clinical information from Elsevier.

Sharing, discovering and citing COVID-19 data and code
A webinar from the NIH.

Open-access data and computational resources to address COVID-19
NIH curated list of links to data sources.

Virtual NIH activities for trainees outside the NIH
Resources from the NIH Office of Intramural Training & Education, including online workshops.

TED Connects
Daily conversations with TED talkers.

Resources from the Council of Graduate Schools for navigating the COVID-19 pandemic

Discussions on the biomedical workforce in the time of COVID-19
A series of discussions hosted by Rescuing Biomedical Research.

Journal of Biological Chemistry


JBC's coronavirus virtual issue presents a retrospective collection of content on coronavirus entry, proteases and host interactions to help researchers build more quickly toward therapeutic endpoints against SARS-CoV-2 and future strains.

See also...
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus